PhRMA’s To-Do List For Part D
This article was originally published in RPM Report
Executive Summary
During a Senate Aging Committee on the Medicare Part D program, Pharmaceutical Research & Manufacturers of America EVP Richard Smith testified on behalf of industry. In a hearing that inevitably included discussion of adding rebates to Part D, Smith offered an alternative vision for improvements. Here are PhRMA’s proposals, excerpted from Smith’s written testimony.